It has two candidates in phase 3 – lurbinectedin for small-cell lung cancer and JZP351 (liposomal daunorubicin and cytarabine) for acute myeloid leukaemia. The deal is also a first partnership ...

The ODAC considered whether the new low dose in combination with daunorubicin and cytarabine had an acceptable safety profile, and to discuss whether event-free survival is an acceptable endpoint ...

Mission Statement: Evidence-based Complementary and Alternative Medicine (eCAM) is an international, peer-reviewed journal that seeks to understand the sources and to encourage rigorous research ...